Abstract
Aim: As being a
heterogenous population but having different pools of self-renewing cells,
amniotic fluid cells (AFCs) have been considered as promising cell sources for
regenerative medicine owing to their multipotency and effective reprogramming
capacity. AFCs can more easily and effectively be
reprogrammed than terminally differentiated cells to generate induced
pluripotent stem cells (iPSCs) by transfectional and chemical strategies. But
stem cell dynamics and differentiation capacity of AFCs into multiple lineages
were poorly understood. The aim of this study was to determine the expression
and stem cell characteristics of stem cell pluripotency markers in amniotic
fluid cells. Methods: In this study,
the expression profile of pluripotency markers in AFCs taken from 17 patients
were investigated by conventional RT-PCR by qualitatively. Results: The results showed that all the
pluripotency markers (OCT3/OCT4, SOX2, KLF4, MYC,
KIT, NANOG, DPPA3, DPPA5, FUT4, SALL4) were expressed in AFCs from different
patients but UTF1 is shows a
non-specific expression. Conclusion:
Consequently, our results revealed that AFCs have a unique stem cell profile
and pluripotency markers may be impactful when choosing cells for reprogramming
and regenerative medicine applications.
References
- 1. Roubelakis MG, Trohatou O, Anagnou NP. Amniotic fluid and amniotic membrane stem cells: marker discovery. Stem Cells International 2012, 107836.
- 2. Gholizadeh-Ghalehaziz S, Farahzadi R, Fathi E, Pashaiasl M. A mini overview of isolation, characterization and application of amniotic fluid stem cells. International Journal of Stem Cells 2015; 8(2): 115-120.
- 3. Klemmt PA, Vafaizadeh V, Groner B. The potential of amniotic fluid stem cells for cellular therapy and tissue engineering. Expert Opin Biol Ther 2011; 11(10): 1297-1314.
- 4. Galende E, Karakikes I, Edelman L, Desnick AJ, Kerenyi T, Khoueiry G, Lafferty J, McGinn JT, Brodman M, Fuster V, Hajjar R, Polgar K. Amniotic fluid cells are more efficiently reprogrammed to pluripotency than adult cells. Cellular Reprograming 2010; 12(2): 117-125.
- 5. Roubelakis MG, Pappa KI, Bitsika V, Zagoura D, Vlahou A, Papadaki HA, Antsaklis A, Anagnou NP. Molecular and proteomic characterization of human mesenchymal stem cells derived from amniotic fluid: comparison to bone marrow mesenchymal stem cells. Stem Cells Dev 2007; 16(6): 931-952.
- 6. Li C, Zhou J, Shi G, Ma Y, Yang Y, Gu J, Yu H, Jin S, Wei Z, Chen F, Jin Y. Pluripotency can be rapidly and efficiently induced in human amniotic fluid-derived cells. Human Molecular Genetics 2009; 18(22): 4340-4349.
- 7. Ditadi A, Coppi P, Picone O, Gautreau L, Smati R, Six E, Bonhomme D, Ezine S, Frydman R, Cavazzana-Calvo M, Andre-Schmutz I. Human and murine amniotic fluid c-Kit+/Lin- cells display hematopoietic activity. Blood 2017; 113(17): 3953-3960.
- 8. Bossolasco P, Montemurro T, Cova L, Zangrossi S, Calzarossa C, Buiatiotis S, Soligo D, Bosari S, Silani V, Deliliers LG, Rebulla P, Lazzari L. Molecular and phenotypic characterization of human amniotic fluid cells and their differentiation potential. Cell Research 2006; 16: 329-336.
- 9. Kang JH, Park HJ, Jung YW, Shim SH, Sung SR, Park JE, Cha DH, Ahn EH. Comparative transriptome analysis of cell-free fetal RNA from amniotic fluid an RNA from amniocytes in uncomplicated pregnancies. Plos One 2015;10(7):1-13.
- 10. Chen L., Daley GQ. Molecular basis of pluripotency. Human Molecular Genetics 2008; 17(1): 23-27.
- 11. Liu X, Huang J, Chen T, Wang Y, Xin S, Li J, Pei G, Kang J. Yamanaka factors critically regulate the developmental signaling network in mouse embryonic stem cells. Cell Research 2008; 18: 1177-1189.
- 12. Zhao W, Ji X, Zhang F, Li L, Ma L. Embryonic stem cell markers. Molecules 2012; 17: 6196-6236.
- 13. Pazhanisamy S. Adult stem cells and embryonic stem cell markers. Mater Methods 2013; 3: 200.
- 14. Feng C, Jia YD, Zhao XY. Pluripotency of induced pluripotent stem cells. Genomics Proteomics Bioinformatics 2013; 11: 299-303.
- 15. Ramirez JM, Gerbal-Chaloin S, Milhavet O, Qiang B, Becker F, Assou S, Lemaitre JM, Hamamah S, De Vos J. Brief report: benchmarking human pluripotent stem cell markers during differentiation into the three germ layers unveils a striking heterogenity – all markers are not equal. Stem Cells 2011; 29:1469-1474.
- 16. Maguire CT, Demarest BL, Hill JT, Palmer JD, Brothman AR, Yost HJ, Condic ML. Genome-wide analysis reveals the unique stem cell identity of human amniocytes. PloS One 2013; 8(1): 1-16.
- 17. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162(1): 156-159.
- 18. Kunsaki SM, Freedman DA, Fauza DO. Fetal tracheal reconstruction with cartiaginous grafts engineered from mesenchymal amniocytes. Journal of Pediatric Surgery 2006; 41: 675-682.
- 19. Gekas J, Walther G, Skuk D, Bujold E, Harvey I, Franc O, Bertrand F. In-vitro and in-vivo study of human amniotic fluid-derived stem cell differentiation into myogenic lineage. Clinical Experimental Medicine 2010; 10: 1-6.
- 20. Ge X, Wang IE, Toma I, Sebastiano V, Liu J, Butte MJ, Pera RAR, Yang PC. Human mesenchymal stem cell-derived induced pluripotent sttem cells may generate a universal source of cardiac cells. Stem Cells and Development 2012; 21(15): 2798-2808.
- 21. Anchan RM, Quaas P, Gerami-Naini B, Bartake H, Griffin A, Zhou Y, Eaton JL, George LL, Naber C, Turbe-Doan A, Park JP, Hornstein MD, Maas RL. Amniocytes can serve a dual function as a source of iPS cells and feeder layers. Human Molecular Genetics 2011; 20(5): 962-974.
- 22. Kunisaki SM, Armant M, Kao SG, Stevenson K, Kim H, Fauza DO. Tissue engineering from human mesenchymal amniocytes: a prelude to clinical trials. Journal of Pediatric Surgery 2007; 42: 974-980.
- 23. Kaviani A, Guleserian K, Perry TE, Jenningd RW, Ziegler MM, Fauza DO. Fetal tissue engineering from amniotic fluid. Journal of the American College of Surgeons 2003; 196: 592-597.
Abstract
Amaç: Amniyotik sıvı farklı
seviyelerde kendini yenileyebilen hücre gruplarından oluşmaktadır ve bu
hücrelerin kök hücre özellikleri henüz tam olarak karakterize edilmemiştir. Son
yıllarda amniyotik sıvı hücreleri (AFC) rejenaratif tıp için umut veren kök hücre
kaynağı olarak görülmektedir. AFC’ler transfeksiyonel ve kimyasal stratejiler
ile indüklenmiş pluripotent kök hücre (iPSC)’ler oluşturmak için terminal
olarak farklılaşmış hücrelerden daha kolay ve etkili bir şekilde yeniden
programlanabilirler. Fakat AFC’lerin kök hücre potansiyelleri ve farklı hücre
soylarına farklılaşma kapasitesi tam olarak anlaşılamamıştır. Bu çalışmada amniyotik
sıvı hücrelerinde kök hücre pluripotensi belirteçlerinin ifadelerinin ve kök
hücre karakterlerinin belirlenmesi amaçlanmıştır.
Yöntem: Bu çalışmada, 17 amniyon
sıvısından elde edilen AFC’lerde pluripotensi belirteçlerinin ifade edilip
edilmediği geleneksel RT-PCR ile kalitatif olarak araştırılmıştır. Bulgular: Elde edilen sonuçlar, farklı
hastalardan alınan AFC örneklerinde incelenen pluripotensi belirteçlerinden OCT3/OCT4, SOX2, KLF4, MYC, KIT, NANOG,
DPPA3, DPPA5, FUT4, SALL4’ün ifade edildiğini, UTF1 için ise non-spesifik
ifade olduğunu göstermektedir.
Sonuç: Elde edilen bulgular doğrultusunda
AFC’nin kendine özgü bir kök hücre profiline sahip olduğu ve pluripotensi
belirteçlerinin yeniden programlama ve rejeneratif tıp uygulamaları için hücre
seçiminde etkili şekilde kullanılabileceği düşünülmektedir.
References
- 1. Roubelakis MG, Trohatou O, Anagnou NP. Amniotic fluid and amniotic membrane stem cells: marker discovery. Stem Cells International 2012, 107836.
- 2. Gholizadeh-Ghalehaziz S, Farahzadi R, Fathi E, Pashaiasl M. A mini overview of isolation, characterization and application of amniotic fluid stem cells. International Journal of Stem Cells 2015; 8(2): 115-120.
- 3. Klemmt PA, Vafaizadeh V, Groner B. The potential of amniotic fluid stem cells for cellular therapy and tissue engineering. Expert Opin Biol Ther 2011; 11(10): 1297-1314.
- 4. Galende E, Karakikes I, Edelman L, Desnick AJ, Kerenyi T, Khoueiry G, Lafferty J, McGinn JT, Brodman M, Fuster V, Hajjar R, Polgar K. Amniotic fluid cells are more efficiently reprogrammed to pluripotency than adult cells. Cellular Reprograming 2010; 12(2): 117-125.
- 5. Roubelakis MG, Pappa KI, Bitsika V, Zagoura D, Vlahou A, Papadaki HA, Antsaklis A, Anagnou NP. Molecular and proteomic characterization of human mesenchymal stem cells derived from amniotic fluid: comparison to bone marrow mesenchymal stem cells. Stem Cells Dev 2007; 16(6): 931-952.
- 6. Li C, Zhou J, Shi G, Ma Y, Yang Y, Gu J, Yu H, Jin S, Wei Z, Chen F, Jin Y. Pluripotency can be rapidly and efficiently induced in human amniotic fluid-derived cells. Human Molecular Genetics 2009; 18(22): 4340-4349.
- 7. Ditadi A, Coppi P, Picone O, Gautreau L, Smati R, Six E, Bonhomme D, Ezine S, Frydman R, Cavazzana-Calvo M, Andre-Schmutz I. Human and murine amniotic fluid c-Kit+/Lin- cells display hematopoietic activity. Blood 2017; 113(17): 3953-3960.
- 8. Bossolasco P, Montemurro T, Cova L, Zangrossi S, Calzarossa C, Buiatiotis S, Soligo D, Bosari S, Silani V, Deliliers LG, Rebulla P, Lazzari L. Molecular and phenotypic characterization of human amniotic fluid cells and their differentiation potential. Cell Research 2006; 16: 329-336.
- 9. Kang JH, Park HJ, Jung YW, Shim SH, Sung SR, Park JE, Cha DH, Ahn EH. Comparative transriptome analysis of cell-free fetal RNA from amniotic fluid an RNA from amniocytes in uncomplicated pregnancies. Plos One 2015;10(7):1-13.
- 10. Chen L., Daley GQ. Molecular basis of pluripotency. Human Molecular Genetics 2008; 17(1): 23-27.
- 11. Liu X, Huang J, Chen T, Wang Y, Xin S, Li J, Pei G, Kang J. Yamanaka factors critically regulate the developmental signaling network in mouse embryonic stem cells. Cell Research 2008; 18: 1177-1189.
- 12. Zhao W, Ji X, Zhang F, Li L, Ma L. Embryonic stem cell markers. Molecules 2012; 17: 6196-6236.
- 13. Pazhanisamy S. Adult stem cells and embryonic stem cell markers. Mater Methods 2013; 3: 200.
- 14. Feng C, Jia YD, Zhao XY. Pluripotency of induced pluripotent stem cells. Genomics Proteomics Bioinformatics 2013; 11: 299-303.
- 15. Ramirez JM, Gerbal-Chaloin S, Milhavet O, Qiang B, Becker F, Assou S, Lemaitre JM, Hamamah S, De Vos J. Brief report: benchmarking human pluripotent stem cell markers during differentiation into the three germ layers unveils a striking heterogenity – all markers are not equal. Stem Cells 2011; 29:1469-1474.
- 16. Maguire CT, Demarest BL, Hill JT, Palmer JD, Brothman AR, Yost HJ, Condic ML. Genome-wide analysis reveals the unique stem cell identity of human amniocytes. PloS One 2013; 8(1): 1-16.
- 17. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162(1): 156-159.
- 18. Kunsaki SM, Freedman DA, Fauza DO. Fetal tracheal reconstruction with cartiaginous grafts engineered from mesenchymal amniocytes. Journal of Pediatric Surgery 2006; 41: 675-682.
- 19. Gekas J, Walther G, Skuk D, Bujold E, Harvey I, Franc O, Bertrand F. In-vitro and in-vivo study of human amniotic fluid-derived stem cell differentiation into myogenic lineage. Clinical Experimental Medicine 2010; 10: 1-6.
- 20. Ge X, Wang IE, Toma I, Sebastiano V, Liu J, Butte MJ, Pera RAR, Yang PC. Human mesenchymal stem cell-derived induced pluripotent sttem cells may generate a universal source of cardiac cells. Stem Cells and Development 2012; 21(15): 2798-2808.
- 21. Anchan RM, Quaas P, Gerami-Naini B, Bartake H, Griffin A, Zhou Y, Eaton JL, George LL, Naber C, Turbe-Doan A, Park JP, Hornstein MD, Maas RL. Amniocytes can serve a dual function as a source of iPS cells and feeder layers. Human Molecular Genetics 2011; 20(5): 962-974.
- 22. Kunisaki SM, Armant M, Kao SG, Stevenson K, Kim H, Fauza DO. Tissue engineering from human mesenchymal amniocytes: a prelude to clinical trials. Journal of Pediatric Surgery 2007; 42: 974-980.
- 23. Kaviani A, Guleserian K, Perry TE, Jenningd RW, Ziegler MM, Fauza DO. Fetal tissue engineering from amniotic fluid. Journal of the American College of Surgeons 2003; 196: 592-597.
Details
| Primary Language | Turkish |
|---|---|
| Subjects | Health Care Administration |
| Journal Section | Articles |
| Authors | |
| Publication Date | December 31, 2019 |
| Submission Date | September 27, 2019 |
| Acceptance Date | October 22, 2019 |
| Published in Issue | Year 2019 Volume: 12 Issue: 3 |
Cite
MEU Journal of Health Sciences Assoc was began to the publishing process in 2008 under the supervision of Assoc. Prof. Gönül Aslan, Editor-in-Chief, and affiliated to Mersin University Institute of Health Sciences. In March 2015, Prof. Dr. Caferi Tayyar Şaşmaz undertook the Editor-in Chief position and since then he has been in charge.
Publishing in three issues per year (April - August - December), it is a multisectoral refereed scientific journal. In addition to research articles, scientific articles such as reviews, case reports and letters to the editor are published in the journal. Our journal, which has been published via e-mail since its inception, has been published both online and in print. Following the Participation Agreement signed with TÜBİTAK-ULAKBİM Dergi Park in April 2015, it has started to accept and evaluate online publications.
Mersin University Journal of Health Sciences have been indexed by Turkey Citation Index since November 16, 2011.
Mersin University Journal of Health Sciences have been indexed by ULAKBIM Medical Database from the first issue of 2016.
Mersin University Journal of Health Sciences have been indexed by DOAJ since October 02, 2019.
Article Publishing Charge Policy: Our journal has adopted an open access policy and there is no fee for article application, evaluation, and publication in our journal. All the articles published in our journal can be accessed from the Archive free of charge.
This work is licensed with Attribution-NonCommercial 4.0 International.